1. A novel Schiff base cobalt(III) complex induces a synergistic effect on cervical cancer cells by arresting early apoptosis stage.
- Author
-
Liao WH, Song XQ, Kong YJ, Bao RD, Li FF, Zhou J, Zhao QH, Xu JY, Xie N, and Xie MJ
- Subjects
- Antineoplastic Agents chemical synthesis, Antineoplastic Agents chemistry, Cell Proliferation drug effects, Cells, Cultured, Cobalt chemistry, Coordination Complexes chemical synthesis, Coordination Complexes chemistry, Drug Screening Assays, Antitumor, Female, Humans, Schiff Bases chemistry, Schiff Bases pharmacology, Uterine Cervical Neoplasms metabolism, Uterine Cervical Neoplasms pathology, Antineoplastic Agents pharmacology, Apoptosis drug effects, Cobalt pharmacology, Coordination Complexes pharmacology, Uterine Cervical Neoplasms drug therapy
- Abstract
A new schiff base cobalt(III) complex [N,N'-bis(2'-hydroxyphenylacetone)-o-ethanediamine] cobalt(III) (M3) has been synthesized and characterized by single X-ray crystallography. The cytotoxicity of complex M3 was evaluated against HeLa, LoVo, A549, A549/cis cancer cell lines, and the normal cell lines LO2 by MTT assays. The IC
50 is in the range of 6.27-22.68 μM, which is somewhat lower than cisplatin on the basis of platinum molar concentration. Furthermore, anticancer mechanistic studies showed that the complex M3 inhibited cell proliferation by blocking DNA synthesis and then acted on nuclear division of HeLa cells over time. Moreover, western blot analysis indicated M3 dramatically decreased the target protein c-Myc and KLF5 expression levels, and activated many signaling pathways including ER stress, apoptosis, cell cycle and DNA damage in HeLa. M3 did not affect proteasomal activity.- Published
- 2021
- Full Text
- View/download PDF